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Decay accelerating factor (DAF) is aglycoprotein present on the surfacesofmany
typesofcells incontactwithplasma, includingerythrocytes, leukocytes, and platelets
(reviewed in reference 1). Asmall amount ofDAFis alsopresentin serum. Numerous
investigators have demonstrated that DAF inhibits the action of C3 convertases on
cell surfaces, and its absence has been shown to be at least partially responsible for
the abnormal sensitivity to lysis by complement exhibited by erythrocytes of pa-
tients with the acquired stem cell disorder paroxysmal nocturnal hemoglobinuria
(PNH) (2). Hereditary absence of DAF has not been previously described.
Tca and Cra are high-frequency human erythrocyte antigens. These antigens are
part of a family ofblood group antigens, designated Cromer related, which are all
absent from the null phenotype cell IFC- , or Inab (3). Recently, Spring and col-
leagues (4) have identified two monoclonal antibodies whichbound to high frequency
red cell antigens absent from the Inab phenotype. They alsodemonstrated thatthese
antibodies, as well as several human antisera to Cromer-related antigens, bound to
a 70-kD glycoprotein when used to stain immunoblots ofhuman erythrocyte mem-
brane proteins. Because the wide tissue distribution ofmAb reactivity, along with
some ofthe biochemical characterization and immunoblotting data, was similar to
that of DAF, we investigated whether the Cromer-related antigens Cra and Tca
resided on the DAF molecule.
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DAF was purified from random donor human erythrocytes by the method of Nicholson-
Weller (5), as modified by Sugita et al. (6). Resultant material was homogeneousas analyzed
by SDS-PAGE and silver staining, and C3 convertase inhibitory activity wasintact, as mea-
suredby the ability ofpurified DAF to inhibit lysisof sheep erythrocytes sensitized with anti-
body and bearing human complement components 1 and 4b (EACI, 4b) (5). This material
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wasused to raise arabbit polyclonal antiserum to DAF (5); the resultingantiserum was non-
reactive with PNH type III cells, indicating that it did not bind to non-DAF erythrocyte
surface proteins.
Antibody reactivity with random donor as well as PNH and phenotypically rare erythro-
cyteswasmeasured by RIAas previously described(7), except that nadiolabeled Staphylococcal
protein A (SPA) was used to detect binding of rabbit antiserum, and F(ab')z sheep antibody
to human Ig (heavy and light chains, Amersham Corp., Arlington Heights, IL) was used
when human blood group antisera were tested. Competitive inhibition assays were performed
as previously described (8), except that purified proteins were solubilized in 0.1% NP-40 at
-700 ug/ml and further diluted in PBS supplemented with 10% BSA. Tc and Cr' antisera
were incubated with purified proteins for 1 h at ambienttemperature before addition of erythro-
cytes. All Cromer-related human antisera were reacted with erythrocytes at 37°C .
Erythrocytes from PNH patients were obtained and separated into populations of type
I (normal) and type III (markedly sensitive to complement) cells as previously described,
usingcobra-venomlysis oftype III cells to obtain type I cells (9) and anti-acetylcholinesterase
affinity chromatography to isolate type III cells (10). None of the patients studied had ap-
preciable numbers of type II cells (with intermediate sensitivity to complement).
Immunoblotting of erythrocyte proteins was performed as previously described (11), ex-
cept that binding of human blood group antibodies was detected using "'I-labeled F(ab')z
sheep antibody to human Ig (-100,000 cpm/100 ul) and PBS, 0.2% Tween 20 buffer, pH
7.4. Reactivity of rabbit antibodies was detected using radiolabeled SPA.
Results
Reactivity of Cromer-related Antibodies with Purified DAF in Solution.
￿
Purified DAF
was tested for its ability to inhibit binding of antisera against the high frequency
Cromer-related antigens Tca and Cr a to random donor erythrocytes. Prior incuba-
tion of antisera with purified DAF was able markedly to inhibit subsequent binding
of both Tca and Cra antibodies to erythrocytes . This effect demonstrated a clear
dose-response relationship (Fig. 1). In contrast, substitution ofpurified In(Lu)-related
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FIGURE 1.
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Competitive inhibition of Cromer-related an-
tisera by purified DAF. Subsaturing dilutionsofantiT'ca (A)
and anti-Cr' (B) were first incubated with purified DAF
(") or purified In(Lu)-related p80 (/) and then reacted
with antigen-positive erythrocytes. Binding of radiolabeled
antibody to human Ig wasthen compared with bindingin
the absence ofinhibitor. The degree ofinhibition produced
by DAF increasedwith increasing amountsof inhibitor; a
similar relationship was notobserved when In(Lu)-related
p80 was used as inhibitor.TELEN ET AL. BRIEF DEFINITIVE REPORT
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TABLE I
Reactivity of Cromer-related Antisera with PNH Erythrocytes
'1 Antisera from different donors .
p80 (12) or use of BSA solution with similar detergent concentrations as the DAF
solution produced no such effect (Fig. 1). Purified DAF was demonstrated by this
method to react with a total of four Tca and Cra antisera (additional data not
shown).
Bindingof Cromer-relatedAntibodies to PNHErythrocytes.
￿
Isolated PNH I and PNH
III erythrocytes were tested, along with unseparated cellsand cells from normal donors,
for their ability to bind antisera to the Cromer-related antigens Tca and Cra. For
all patients and antibodies tested, PNH I cells bound antibodies to Cromer-related
antigens as well or nearly as well as cells from normal donors, while PNH III cells
showed reduced or no binding of antiTca and anti-Cra (Table I). Some Cromer-
related antibodies reacted weakly with PNH III cells; these results could have been
due to contamination of the PNH III cells by small numbers of PNH I cells or to
the presence of small amounts of antibody to other antigens in the antisera used.
Unseparated PNH erythrocytes showed binding of antiTca and anti-Cra inter-
mediate between that obtained with purified PNH I and PNH III cells, as would
be expected.
PNH I and PNH III erythrocytes were also tested by standard agglutination tech-
niques for reactivity with antisera to Cromer-related antigens. Antisena to Cra, Tca,
ITC, West', Dr", and Esa all agglutinated PNH I cells but failed to agglutinate PNH
III cells.
Immunoblotting
￿
When antisera to Tca were used to stain immunoblots of purified
DAF, these antisera showed clear reactivity with DAF protein, while no reactivity
was detected using nonreactive human serum (Fig. 2) or using purified In(Lu)-related
p80 (12), a protein unrelated to DAF (data not shown). Similar data were obtained
with anti-Cra (not shown).
Expression ofDAFby Inab Phenotype Erythrocytes.
￿
When rabbit polyclonal antiserum
to DAF was tested for reactivity with Inab phenotype erythrocytes, these cells showed
Cell type Anti-Tc"
cpm bound, compared with
normal control cells
Anti-TOT Anti-Cr'
Patient 1
Unseparated 22 59 ND
Type I 81 119 ND
Type III 0 27 ND
Patient 2
Unseparated 56 ND 82
Type I 83 ND 97
Type III 21 ND 51
Patient 3
Unseparated ND 31 63
Type I ND 106 105
Type III ND 2 391996
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FIGURE 2 .
￿
Reactivity of anti-
TO with purified DAF and ab-
sence of immunoreactive DAF
in cells oftheCromer-null Inab
phenotype. (A) Tc a antiserum
(lane 1) and normal human
serum (lane 2) were reacted with
purified erythrocyte DAF pro-
tein ; antiTca showed specific
reactivity with DAF . Anti-Cr'
gave similar reactivity (not
shown) . (B)Membrane proteins
from Cromer antigen-positive
erythrocytes (lanes 1, 3, 4, and
6) andInab erythrocytes (lanes
2 and 5) were separatedby SDS-
PAGE, transferred to nitrocel-
lulose, and reacted with rabbit
antiserum to DAF (lanes 1-3)
or normal rabbit serum (lanes
4-6) . Inab cell membrane pro-
teins contained no im-
munoreactive DAF .
minimal reactivity (mean of three experiments = 1 .1 x background cpm, range
= 0.6-1.3) compared with Cr(a+) Tc(a+ ) cells from six donors, which bound anti-
DAF strongly (5.7 x background cpm, range = 3.5-6.6) . Immunoblotting of Inab
erythrocyte membrane proteins with anti-DAF also failed to show reactivity of anti-
body with a specific protein band consistent with the known molecular weight of
DAF (Fig. 2) .
Discussion
These studies have demonstrated that antibodies to the Cromer-related human
blood group antigens Cra and Tca reacted with purified DAF, a glycoprotein that
regulates the activation of thecomplement component C3 on the surface of hemato-
poietic cells. Soluble purified DAFwas able to competitively inhibitbinding ofCromer-
related antibodies to erythrocytes, and antiTca and anti-Cra bound to purified DAF
but not to other proteins in immunoblots . Moreover,PNH III erythrocytes, which
lack DAF, demonstrated reduced or absent reactivity with human antisera to the
Tca and Cra antigens, as well as with antisera to other Cromer-related antigens . In
contrast, PNH I erythrocytes from the same donors reacted normally with these
antisera. These data all demonstrate not only that expression of these antigens is
dependent on expression of DAF but also that these antigens reside on the DAF
molecule . However, ourdata do not provide information regarding the topographic
relationship of these two epitopes to each other or to the functional domain of the
DAF protein . Preliminary studies have shown that binding of Cromer-related anti-
bodies to DAF protein does not inhibit activity ofDAF, as measured by the comple-
ment lysis sensitivity test (13) .
Identification ofDAF as the molecule that carries these Cromer-related blood group
antigens is largely consistent with the biochemical characterization of the protein
identified by Spring and colleagues (4) . However, they were unable to demonstratethe presence ofN-linked glycans by endoglycosidase F treatment oferythrocyte mem-
brane proteins under nonreducing conditions, while DAF has been shown to bear
-3,000 daltons of such oligosaccharides (14). Most likely, the N-linked oligosaccha-
rides of the DAF protein are not available to enzymatic digestion unless the intruchain
disulfide bonds are disrupted. DAF is known to have multiple intruchain disulfide
bonds (15), consistent with observations by Spring and colleagues that Cromer-related
antigens are destroyed by reagents that denature such bonds (4). The known varia-
tion in molecular weight of DAF from various cell lineages (15) is also consistent
with the data obtained with Cromer-related antibodies (4).
Polymorphisms in the Cromer-related antigens are rare, with the most common
being expression of the Tc" antigen, an antigen that occurs in -5% of blacks
(reviewed in reference 16). Since none of the rare Cromer-related antigen pheno-
types have been reported to be associated with hemolytic diseases, such polymor-
phisms most likely do not affect function of the DAF protein as an inhibitor of C3
convertases. However, direct study oferythrocytes with rare Cromer-related pheno-
types is needed to confirm that such polymorphisms are not associatedwith subclin-
ical disease states. Recently, Stafford and colleagues (17) have presented data describing
restriction fragment length polymorphisms ofthe gene encoding DAR Also, Sugita
et al. (6) described aminoacid sequence polymorphisms in the first and fourth amino
acids of DAR However, these polymorphisms are most likely not directly related
to Tc and Cr blood group antigen polymorphisms, since the latter are of quite low
frequency.
Cells of the very rare Inab phenotype bound little or no rabbit polyclonal anti-
body to DAR This extremely rare null phenotype is therefore likely to represent
an inherited inability to express normal DAR Lack of expression of DAF by Inab
cells could be due to defective DAF genes or to a processingor insertion defect similar
to that proposed for PNH . Although persons with the Inab phenotype have not been
described to have hemolytic disease, cells with an isolated DAF defect would be ex-
pected to behave like PNH II cells and thus suffer little hemolysis in vivo (1) . How-
ever, two of the four persons described to have had this phenotype have also had
severe protein-losing enteropathies, suggesting that lack of DAF or lack of another
protein genetically linked to expression of DAF and Cromer-related antigens may
play a critical role in human gastrointestinal pathophysiology.
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